Latest news with #CMOs
Yahoo
21 hours ago
- Business
- Yahoo
CMO Confidence in GenAI Is Higher Than Ever, with Over 80% Expressing Optimism
BCG's Annual Survey of More Than 200 CMOs Reveals That 71% Plan to Invest over $10 Million Annually in GenAI in the Next Three Years One-Third of CMOs Report Improvements in Customer Experience and Content Quality; Fewer Report Efficiency Gains Video Generation, Personalization, and Agentic AI Are Among the Next Wave of CMO Priorities BOSTON, June 2, 2025 /PRNewswire/ -- Despite economic volatility, 71% of CMOs plan to invest more than $10 million annually in GenAI over the next three years, up from 57% last year. According to a new survey from Boston Consulting Group (BCG), optimism among CMOs about GenAI has climbed each year—from 74% in 2023 to 83% in 2025—while concerns have declined rapidly. While over a third of CMOs report improvements in customer experience, content quality, and volume, thanks to GenAI, fewer CMOs than last year cite efficiency gains from increased productivity and the elimination of manual work. Still, 60% of CMOs expect GenAI to drive revenue gains of 5% or more in their focus areas. These are among the findings of BCG's report, titled How CMOs Are Scaling GenAI in Turbulent Times, released today. The report is based on a survey of 200 CMOs across Asia, Europe, and North America, conducted in April and May 2025. "GenAI is rapidly becoming embedded in the marketing function," said Mark Abraham, a BCG managing director and global leader of the firm's personalization business. "Even in the current turbulent macroeconomic environment, we're seeing CMOs invest in shifting from isolated pilots to scaled GenAI use cases, enhancing personalization and marketing operations." Investment in Content Creation, Personalization, and Agentic AI As CMOs explore new applications, they will prioritize investments in pilot areas such as content creation (particularly immersive media and video), AI-powered personalization, and agentic AI: Video generation emerges as the next frontier in content creation, with 30% of CMOs identifying it as their next focus area. Predictive analytics remains critical for personalization, with CMOs citing product recommendations, outreach timing, and next-best content as areas they have fully scaled. More advanced use cases, such as personalized offers, churn prediction, and audience optimization are the next pilot wave. By scaling personalized offers, leading marketers are generating 3x higher returns than those of mass offers. AI agents are reshaping marketing workflows, especially for B2B companies. One-third of B2B CMOs and nearly one-quarter of B2C CMOs cited AI agents as a high investment priority. CMOs Deprioritize ROI Measurement, Focus on Talent Development When asked how they are prioritizing funds to enhance the digital customer experience, CMOs ranked the use of GenAI to measure marketing ROI last. Many are relying on previous investments in first-party data collection while underinvesting in the measurement of marketing ROI. In parallel, CMOs are sustaining investment in talent development. With GenAI talent in short supply, many are upskilling their teams with hackathons, AI incubator studios, and hands-on demos instead of relying on external hires. "In conversations with CMOs, it's clear that GenAI has become a core part of how modern marketing teams operate," said Lauren Wiener, a BCG managing director and global lead for the firm's Marketing practice. "What separates the winners is a commitment not just to scaling the technology, but to empowering the people who use it. Those CMOs investing in tools and talent are the ones rewriting the playbook." Download the publication here: Media Contact:Eric Gregoire+1 617 850 About Boston Consulting GroupBoston Consulting Group partners with leaders in business and society to tackle their most important challenges and capture their greatest opportunities. BCG was the pioneer in business strategy when it was founded in 1963. Today, we work closely with clients to embrace a transformational approach aimed at benefiting all stakeholders—empowering organizations to grow, build sustainable competitive advantage, and drive positive societal impact. Our diverse, global teams bring deep industry and functional expertise and a range of perspectives that question the status quo and spark change. BCG delivers solutions through leading-edge management consulting, technology and design, and corporate and digital ventures. We work in a uniquely collaborative model across the firm and throughout all levels of the client organization, fueled by the goal of helping our clients thrive and enabling them to make the world a better place. View original content to download multimedia: SOURCE Boston Consulting Group (BCG) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
3 days ago
- Business
- Fast Company
Marketing in an age of economic uncertainty
Let's get this out of the way: We constantly live in uncertain times. Periods of tranquility are actually an aberration, if not an illusion. The relationship between marketing budgets and economic volatility has always been complex. What we're witnessing isn't just the usual ebb and flow of consumer confidence or standard market corrections. It's an unprecedented convergence of tariff confusion, inflationary pressures, supply chain disruptions, and debt refinancing challenges. As I talk to CMOs and marketing leaders across industries, one word keeps surfacing: paralysis. Decision makers find themselves frozen, unsure whether to commit to long-term advertising contracts, unable to accurately forecast costs, and struggling to craft messaging that resonates in a consumer landscape where spending power is increasingly unpredictable. The historical perspective: Who thrives in downturns? When I look back at previous economic contractions—particularly 2008 and 2020—a clear pattern emerges that separates survivors from thrivers. In 2008, as financial markets collapsed, brands like Amazon, Netflix, and Hyundai didn't retreat. They advanced. Netflix invested heavily in its streaming service during the financial crisis, laying the groundwork for its eventual dominance. Hyundai introduced its ground-breaking 'Assurance Program,' allowing customers to return newly purchased vehicles if they lost their jobs—a true masterstroke that increased Hyundai's market share while competitors were seeing double-digit sales declines. The 2020 pandemic presented similar divergent paths. While many brands slashed marketing budgets in panic, companies like Zoom and DoorDash significantly increased their marketing investments, recognizing the unique moment to capture market share when consumers were rapidly forming new habits. The common thread? These companies didn't view marketing as a discretionary expense to be cut during uncertainty. They saw it as a strategic lever, one that should be pulled harder during hard times. 4 strategic approaches for the uncertainty-conscious marketer Here's what the most forward-thinking marketers are doing now to navigate the choppy waters ahead: They're embracing flexibility in all media contracts. The days of rigid, long-term commitments are giving way to more agile arrangements that allow for budget reallocation as economic conditions shift. This means negotiating pause clauses, shorter commitment windows, and performance-based terms that protect all contracted parties. Budgets are shifting toward measurable, adaptable channels. While social media and traditional media face the deepest anticipated cuts (41% and 43% respectively), digital advertising continues to gain market share despite economic concerns. Digital is projected to encompass up to 79% of total ad spend by 2030, up from its current 67%. Message content is being entirely rethought. In the face of economic anxiety, brands need messaging that acknowledges reality while providing genuine value. We're seeing this play out in automotive advertising, where some manufacturers are emphasizing their American manufacturing credentials. Ford's 'From America, For America' campaign represents a strategic positioning that resonates in an era of tariff concerns. As Hyundai, in 2008, these advertisers are using the moment to emphasize their particular brand's appeal. AI is being leveraged not just for cost cutting but for scenario planning. The most sophisticated marketing teams are using AI to model multiple economic outcomes and prepare messaging, budget allocations, and channel strategies for each scenario. The creative reset: How agencies have already adapted It's worth noting that the industry isn't starting from scratch in facing these challenges. Client behavior on creative development has undergone a dramatic transformation over the past several years. The best independent agencies have already restructured their operations in response. Gone are the days of lengthy creative development cycles and rigid campaign frameworks. Anticipating these changes years ago, independent shops have largely embraced agile methodologies that align perfectly with today's economic realities. In many ways, the independent agency sector has already prepared for exactly this kind of destabilizing environment. They've built their businesses around speed and adaptability rather than scale and standardization. As such, they're uniquely positioned to help steer brands through bumps ahead without sacrificing creative impact or market presence. Brand versus performance in uncertain times Perhaps the most critical strategic question facing marketers is how to balance brand building against performance marketing when budgets contract. Historical data consistently shows that brands maintaining or increasing their share of voice during downturns emerge in stronger positions when markets recover. Yet short-term revenue pressures make performance marketing irresistibly tempting when every dollar must be justified. The smart play here isn't choosing one over the other but reimagining how all of these factors work together. Performance marketing can be designed to build brand equity simultaneously. Brand marketing can incorporate more direct response elements. The artificial wall between these disciplines must come down to survive economic headwinds. Opportunity within adversity The brands that will emerge strongest from this period of uncertainty won't be those with the largest budgets, but those with the clearest strategic vision, the most agile execution, and the courage to maintain presence when competitors retreat. Economic uncertainty doesn't change the fundamental truth that share of voice leads to share of market. It simply raises the stakes and rewards those who can maintain their voice when others fall silent. Looking at the latter half of 2025, the marketing leaders who view this period not as a time to hide but as a rare opportunity to stand out will be the ones writing the success stories we'll be studying for years to come.
Yahoo
6 days ago
- Business
- Yahoo
Outsourcing Trend in Pharma and Biotech Boosts Demand for End-to-End Nanoparticle CDMO Solutions
This report emphasizes the strategic importance of nanoparticle manufacturing in biopharma and materials sectors, highlighting increased demand for outsourcing complex synthesis to specialized CMOs. The report includes recent global tariff developments and their impact. Key segments covered include Metal and Lipid Nanoparticles, and significant growth is projected in the U.S. and Chinese markets. Nanoparticle Contract Manufacturing Market Dublin, May 28, 2025 (GLOBE NEWSWIRE) -- The "Nanoparticle Contract Manufacturing - Global Strategic Business Report" has been added to global market for Nanoparticle Contract Manufacturing was valued at US$2.8 Billion in 2024 and is projected to reach US$4 Billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Nanoparticle Contract Manufacturing market. Why Is Nanoparticle Contract Manufacturing Gaining Strategic Importance Across the Biopharma and Materials Sectors?Nanoparticle contract manufacturing has become a critical enabler in the development and commercialization of nanotechnology-based products across pharmaceuticals, biotechnology, cosmetics, and advanced materials. As nanoparticle formulations often require complex synthesis, purification, and characterization steps, outsourcing these processes to specialized contract manufacturing organizations (CMOs) provides scale, regulatory alignment, and technical expertise that many innovators lack in-house. These partnerships allow startups, academic spin-offs, and even large pharma players to accelerate product development while reducing capital expenditure on high-end nano fabrication the biopharmaceutical sector, nanoparticles are increasingly used as drug delivery vehicles - particularly in liposomal formulations, lipid nanoparticles (LNPs) for mRNA delivery, and polymer-based nanosuspensions. Their ability to enhance solubility, target delivery, control release, and bypass biological barriers has made them indispensable in oncology, vaccines, and CNS drugs. The rising complexity of these products, coupled with tight regulatory controls around particle size, morphology, and purity, has made contract manufacturers integral to the nanomedicine supply chain. Beyond pharma, industries like food, personal care, and electronics also rely on CMOs for high-precision nanoparticle production under GMP and ISO Are Technology Platforms, Quality Systems, and Process Optimization Enhancing CMO Capabilities?Contract manufacturers specializing in nanoparticles are investing in scalable and reproducible synthesis technologies such as microfluidics, high-pressure homogenization, emulsion-diffusion, supercritical fluid processing, and solvent evaporation. These techniques allow tight control over particle size distribution, zeta potential, encapsulation efficiency, and drug loading - key metrics for regulatory success and therapeutic performance. Continuous manufacturing platforms are also being adopted for better yield consistency and process validation, especially in high-throughput nanocarrier analytical capabilities are a differentiator in this space, with CMOs offering advanced particle characterization via dynamic light scattering (DLS), scanning electron microscopy (SEM), atomic force microscopy (AFM), and HPLC. Regulatory-compliant quality management systems (QMS) ensure data integrity, lot traceability, and sterility assurance for clinical and commercial batches. Some CDMOs are also integrating formulation services, aseptic fill-finish, and cold chain logistics into their nanoparticle manufacturing offerings, delivering an end-to-end solution for nanomedicine developers. This bundling of services reduces the coordination burden and regulatory complexity for Application Areas and Client Segments Are Fueling Demand for Nanoparticle Manufacturing Services?Pharmaceutical and biotech companies account for the majority of demand, particularly those developing nanocarriers for anticancer drugs, mRNA therapeutics, gene editing tools, and long-acting injectables. The success of LNP-based COVID-19 vaccines has accelerated investment in nanoparticle platforms for nucleic acid delivery, prompting both established players and new entrants to seek contract manufacturing support. Dermatological and ophthalmic drugs are also using nanoparticles to enhance bioavailability and targeting healthcare, the cosmetics industry uses nanoparticles for UV filtration, anti-aging actives, and skin absorption enhancers. Food and beverage companies are exploring nano-encapsulation for flavor preservation and nutrient fortification. Electronics and energy firms require nanoparticle solutions for batteries, coatings, and conductive inks, albeit at different scales and compliance requirements. Startups and academic labs often rely on CMOs for pilot-scale runs, feasibility studies, and regulatory documentation. As nanoparticle-enabled products diversify, demand for specialized and vertically integrated CMOs continues to Is Driving Long-Term Growth and Differentiation in the Nanoparticle Contract Manufacturing Market?The growth in the nanoparticle contract manufacturing market is driven by the proliferation of nano-enabled products, accelerated biotech innovation, and increasing preference for outsourcing complex and capital-intensive processes. Strategic collaborations between drug developers and CDMOs are reducing time-to-market, de-risking development pipelines, and ensuring regulatory alignment in increasingly competitive therapeutic areas. Demand is being reinforced by government funding for nanomedicine research, orphan drug designations for nanoparticle-based therapies, and rising interest in personalized differentiation is occurring through proprietary technology platforms, regulatory expertise, and the ability to support both early-phase and commercial-scale production. CMOs that can co-develop nanoparticle IP, offer formulation customization, and navigate global regulatory frameworks are especially well-positioned. Future trends include the expansion of green chemistry approaches, machine learning-driven process modeling, and modular cleanroom facilities tailored for nano-scale production. As nanoparticles become foundational to innovation across industries, contract manufacturers will play an increasingly strategic role in converting scientific potential into commercially viable ScopeThe report analyzes the Nanoparticle Contract Manufacturing market, presented in terms of market value (US$ Thousand). The analysis covers the key segments outlined Type of Nanoparticles (Metal Nanoparticles, Lipid Nanoparticles, Other Types of Nanoparticles) Manufacturing Scale (Commercial Manufacturing Scale, Clinical Manufacturing Scale, Pre-clinical Manufacturing Scale) Application (Therapeutics Application, Diagnostics Application, Vaccines Application) End-Use (Pharmaceutical Companies End-Use, Biotechnology Companies End-Use) Key Insights: Market Growth: Understand the significant growth trajectory of the Metal Nanoparticles segment, which is expected to reach US$2.6 Billion by 2030 with a CAGR of a 6.9%. The Lipid Nanoparticles segment is also set to grow at 5.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $724.2 Million in 2024, and China, forecasted to grow at an impressive 6.4% CAGR to reach $646.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as American Elements, Ardena Holding, Ascendia Pharmaceuticals, AstraZeneca, AVANSA Technology & Services and more. Tariff Impact Analysis: Key Insights for 2025Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments and incorporates forward-looking insights into the market analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and Attributes: Report Attribute Details No. of Pages 194 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $2.8 Billion Forecasted Market Value (USD) by 2030 $4 Billion Compound Annual Growth Rate 6.5% Regions Covered Global Key Topics Covered: MARKET OVERVIEW World Market Trajectories Nanoparticle Contract Manufacturing - Global Key Competitors Percentage Market Share in 2025 Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 FOCUS ON SELECT PLAYERS Some of the 32 companies featured in this Nanoparticle Contract Manufacturing market report include: American Elements Ardena Holding Ascendia Pharmaceuticals AstraZeneca AVANSA Technology & Services BBI Solutions (Novacyt Group) BioVectra Inc. CordenPharma International Cytodiagnostics Inc. Encapsula NanoSciences Evonik Industries Fortis Life Sciences FUJIFILM Corporation LSNE Contract Manufacturing Merck MyBiotech Nano Labs Corporation nanoComposix, Inc. Nanoscale Corporation Nanoshel MARKET TRENDS & DRIVERS Growth in Nanomedicine Pipelines Drives Demand for Specialized Contract Manufacturing Services Rise in Targeted Drug Delivery Systems Spurs Adoption of Nanoparticle Formulations Expansion of mRNA and Nucleic Acid-Based Therapeutics Strengthens Business Case for Lipid Nanoparticles Outsourcing Trend in Pharma and Biotech Boosts Demand for End-to-End Nanoparticle CDMO Solutions Emergence of Personalized Nanomedicine Expands Addressable Market for Custom Particle Engineering Increased Complexity in Regulatory Filings Throws the Spotlight on GMP-Compliant CDMOs Collaborative Drug Development Models Propel Growth in Specialized Manufacturing Partnerships Rapid Commercialization of RNA-Based Vaccines Drives Demand for Scalable Nanoparticle Production Innovation in Polymer and Lipid Nanoparticles Enhances Customization Potential Proliferation of Oncology Nanotherapeutics Fuels Growth in High-Precision Contract Manufacturing Investment in Containment and Sterile Facilities Strengthens Capabilities of Leading CDMOs Surging Need for Small-Batch Clinical Manufacturing Drives Flexibility in CDMO Offerings Integration of Process Analytical Technology (PAT) Enables Real-Time Particle Size Control Global Regulatory Harmonization Efforts Simplify Cross-Border Market Entry for Contract Manufacturers Application of AI and ML in Process Design Supports Optimization and Cost Reduction Increasing Use of Nanoparticles in Cosmetics and Nutraceuticals Broadens End-User Base Establishment of Nano Innovation Hubs and Tech Transfer Centers Spurs Regional CDMO Expansion Demand for Surface Functionalization Services Generates Differentiation Opportunities Rising Emphasis on Sustainable Nanoparticle Synthesis Presents Greener Manufacturing Avenues Shortage of Specialized Talent and Equipment Poses Scalability Challenges for Smaller CDMOs Strategic Alliances Between Pharma Giants and Specialized CDMOs Propel Innovation in Delivery Platforms For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Nanoparticle Contract Manufacturing Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Forbes
23-05-2025
- Business
- Forbes
Why CMOs Can't Afford To Ignore Hispanic Marketing Now
The signs of an economic recession are becoming increasingly difficult to ignore: declining consumer confidence, a cooling housing market, and persistent market volatility. As Chief Marketing Officers (CMOs) face mounting pressure to trim budgets and optimize marketing investments, critical decisions must be made about where to allocate resources—and where to cut back. Over the past few weeks, as companies have started reporting weaker sales during Q1, several mentioned the Hispanic consumer as a soft driver of these results, and some recognized the need for additional focus and investment in this segment to reverse their performance. Historically, one of the first areas to see reductions during economic downturns has been multicultural marketing. Often deemed "incremental" or "nice to have," these investments have been deprioritized in favor of what is perceived as core marketing strategies. However, in 2025, taking this same approach could prove to be a costly mistake—particularly when it comes to the Hispanic consumer segment. Hispanics are the largest and fastest-growing ethnic minority group in the United States, accounting for nearly 20% of the U.S. population, and 51% of the population growth when compared to the previous census, according to the U.S. Census Bureau. This figure is projected to rise to 28% by 2060. Not only is this demographic growing rapidly, but it also wields significant economic clout. In 2022, the total buying power of U.S. Hispanics reached an estimated $2.8 trillion, making it equivalent to the world's fifth-largest GDP if it were a standalone economy. Moreover, Hispanic consumers are disproportionately younger than the general population, with a median age of 30 compared to 38 for the overall U.S. population. This represents a critical opportunity for brands targeting Millennials, Gen Z, and emerging Gen Alpha consumers. The Hispanic segment is not just a growing market—it's where the future of consumer spending lies. In times of economic uncertainty, it might seem logical to focus solely on "safe bets," but brands that overlook the Hispanic segment risk alienating a critical audience that can drive growth even during a downturn. Moreover, research has helped marketers understand that investment in Hispanic creative can yield a higher ROI than investment in non-Hispanic creative, so the concept of 'safe bets' also needs to be revisited. Here are six key actions CMOs should consider when it comes to Hispanic marketing investments in 2025: 1. Invest Where the Growth Is The Hispanic consumer segment has been a consistent driver of the U.S. population and economic growth. CMOs should allocate at least 10% of their marketing budget to Hispanic-specific programs that leverage culturally relevant channels and messaging. Platforms like Univision, Telemundo, and digital-first spaces such as TikTok, Instagram, and YouTube are particularly effective for engaging this demographic. 2. Craft Messaging That Resonates During a recession, consumers are more drawn to messages that highlight comfort, stability, and family. These themes align closely with core Hispanic cultural values, making it essential for brands to craft campaigns that feel authentic and relatable. Highlighting the importance of home, family, and resilience can create emotional connections that translate into long-term brand loyalty. 3. Prioritize Storytelling That Feels Familiar Hispanic consumers respond well to storytelling that is contextual, entertaining, and infused with humor. Ads that incorporate language, humor, cultural traditions, and everyday scenarios can create a sense of familiarity and trust. 4. Double Down on Loyalty Strategies Hispanic consumers are highly brand-loyal, especially when brands make an effort to acknowledge and celebrate their cultural identity. Loyalty programs that offer personalized rewards, community engagement, or exclusive experiences can deepen the connection with this audience. Importantly, brands should ensure that loyalty strategies are inclusive and consider specific cultural nuances. 5. Emphasize Value without Sacrificing Quality In a recession, value-driven messaging is key, but it shouldn't compromise quality. Hispanic consumers are discerning shoppers who appreciate brands that offer value alongside premium experiences. By emphasizing affordability, durability, and utility—along with culturally relevant branding—companies can remain relevant even in challenging times. 6. Consider Hispanic Consumers as Trendsetters We've all heard that 'necessity is the mother of all invention,' and periods of economic uncertainty when consumers feel pressured, can unlock new consumption behaviors, innovative uses of products and services, and unique combinations that haven't been seen before. Think, for example, about the launch of Airbnb in 2008 during the recession or the launch of Old Navy in the early 90s, which focused on cost-conscious families. Investing in consumer research, ethnographic studies, and in-depth consumer connections will unlock new insights that can benefit businesses both short and long term. If your target audience includes any of the following, a multicultural marketing strategy is no longer optional—it's essential: • 18-35-year-olds - Millennials and Gen Zers are among the most diverse generations in U.S. history, with Hispanics making up a significant portion. • Tweens and teens - Nearly 25% of U.S. children under 18 are Hispanic, making this demographic critical for brands with long-term ambitions. • Small-business owners - According to the Stanford Latino Entrepreneurship Initiative, Hispanic entrepreneurs are starting businesses at a rate three times higher than that of the general population. • Geographically concentrated markets - States like Texas, Florida, New York, and California are home to more than half of the U.S. Hispanic population. • Families - Hispanic households are more likely to include children and extended family members, making family-centric marketing strategies particularly effective. In previous recessions, brands that maintained—or even increased—their marketing investments emerged stronger and more competitive when the economy rebounded. Today, the Hispanic consumer segment represents a unique opportunity to future-proof your brand and drive meaningful growth, even in the face of economic uncertainty. For CMOs, the question isn't whether to invest in Hispanic marketing—it's whether you can afford not to.
Yahoo
20-05-2025
- Business
- Yahoo
Topical Drugs Contract Manufacturing Industry Report 2025-2030: Demand for Dermatological Treatments and Non-Invasive Drug Delivery Drives CMO Market Expansion
India, China, and South Korea Offer Competitive Pricing and Rapid GMP-Compliant Infrastructure Growth Dublin, May 20, 2025 (GLOBE NEWSWIRE) -- The "Topical Drugs Contract Manufacturing Market Size, Share & Trends Analysis by Product Type (Semi-Solid Formulations, Solid Formulations), Scale of Operation (Clinical), End-use (Pharmaceutical Companies), Region, with Growth Forecasts, 2025-2030" report has been added to Topical Drugs Contract Manufacturing Market was valued at USD 29.25 Billion in 2024, and is projected to reach USD 54.55 Billion by 2030, rising at a CAGR of 11.05%. Currently, the global market for contract manufacturing of topical drugs is currently experiencing significant growth, driven by evolving therapeutic needs, outsourcing trends, and advancements in technology. Moreover, with the increasing prevalence of dermatological conditions, coupled with a rising geriatric population and a preference for non-invasive drug delivery methods such as creams, gels, ointments, sprays, and transdermal patches has made outsourcing services like Contract Manufacturing Organizations (CMOs) essential for optimizing costs, ensuring regulatory compliance, and enhancing production capabilities. In addition, CMOs offer numerous advantages that support streamline operations, lower in-house manufacturing expenses, and speed up product commercialization, further contributing to market expansion. In addition, with the rising consumer demand for topical drugs, outsourcing has become a strategic priority, particularly for semi-solid and transdermal product lines that require specialized expertise and adaptable infrastructure. Furthermore, cost dynamics play a crucial role in the growth of the market. Based on the pricing analysis, the North America provides high-quality manufacturing that complies with regulatory standards, while the Asia-Pacific's countries like India, China, and South Korea offers more cost-effective production options with growing capabilities. Factors such as lower labor costs, supportive government policies, and a developing infrastructure complaint with Good Manufacturing Practices (GMP) are fueling the market in Asia-Pacific. Furthermore, technological innovations such as continuous manufacturing, nanoencapsulation, advanced homogenization, and 3D printing are improving formulation accuracy, bioavailability, and batch consistency. These advancements support the CMOs to meet complex product demands and meet rising consumer expectations for efficacy and pricing models are evolving with aligning financial results with performance. However, external factors like U.S. tariffs on imported active pharmaceutical ingredients (APIs) and excipients have created cost pressures in the supply chain, particularly impacting exporters. Despite these challenges, the market is expected to witness growth during the forecast period. Likewise, strategic initiatives and accelerating product launches drive the market. For instance, in July 2024, Arcutis Biotherapeutics, Inc. announced the release of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in both adults and children under 6 in the U.S. This new cream, which is applied once daily and contains no steroids, provides quick relief from symptoms and reduces itching, allowing for better long-term management of the condition. Such innovations are expected to further propel the market during the forecast Drugs Contract Manufacturing Market Report Highlights The semi-solid formulations segment dominated the market, with a share of 65.54% in 2024. This growth is driven by the increasing prevalence of skin diseases, patient preferences for targeted therapies, the convenience of semi-solid formulations, and the demand for improved drug absorption, stability, and aesthetic appeal within both therapeutic and cosmetic sectors. Based on the scale of operation, the commercial segment held the largest market share in 2024, attributed to the growing trend toward outsourcing, increased demand for dermatological and transdermal therapies, regulatory compliance, increased cost efficiency, and the rising complexity of formulations that require specialized manufacturing expertise. The pharmaceutical companies segment held the largest market share in 2024 based on end-use. These companies leverage CMO services due to increasing demand for non-invasive therapies, treatments for chronic skin conditions, improved patient compliance, and opportunities within cosmetic dermatology and advanced transdermal drug delivery systems. North America is expected to register a growth rate of 10.37% CAGR over the forecast period due to the rising number of contract manufacturing organizations(CMOs) in countries such as the U.S. and Canada. In addition, the availability of a skilled workforce and regulatory scenarios are expected to significantly contribute to the market's expansion in this region. Why Should You Buy This Report? Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments. Competitive Landscape: Explore the market presence of key players. Future Trends: Discover the pivotal trends and drivers shaping the future of the market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. This report addresses: Market intelligence to enable effective decision-making Market estimates and forecasts from 2018 to 2030 Growth opportunities and trend analyses Segment and regional revenue forecasts for market assessment Competition strategy and market share analysis Product innovation listings for you to stay ahead of the curve Key Attributes Report Attribute Details No. of Pages 120 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $29.25 Billion Forecasted Market Value (USD) by 2030 $54.55 Billion Compound Annual Growth Rate 11% Regions Covered Global The companies profiled in this Topical Drugs Contract Manufacturing market report include: MedPharm DPT Laboratories Ltd. Cambrex Corporation Kindeva Drug Delivery AbbVie Contract Manufacturing NextPharma Catalent Pharma Solutions Thermo Fisher Scientific Lonza Group The Lubrizol Corporation SGS SA Bora Pharmaceutical CDMO For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
